Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

NCT01835145 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

NIH

Sponsor class

Conditions

Recurrent Uveal Melanoma
Stage III Uveal Melanoma AJCC v7
Stage IIIA Uveal Melanoma AJCC v7
Stage IIIB Uveal Melanoma AJCC v7
Stage IIIC Uveal Melanoma AJCC v7
Stage IV Uveal Melanoma AJCC v7

Interventions

DRUG: Cabozantinib S-malate
DRUG: Dacarbazine
OTHER: Laboratory Biomarker Analysis
DRUG: Temozolomide

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]